Almac pens deal with Merck & Co

29 April 2020

UK-based Almac Discovery has announced a research tie-up with US pharma giant Merck & Co (NYSE: MRK) focusing on the generation of new small molecule inhibitors against specified deubiquitinase (DUB) targets for a range of neurodegenerative and other diseases.

Part of the privately-held Almac Group, the company is experienced in the field of DUBs. Its assay and drug-finding platform, Ubi-Plex, seeks to identify and develop new inhibitors against a large number of therapeutically relevant DUBs.

Almac Discovery and Merck, which is known outside North America as MSD, will initially collaborate in a two-year joint research program with the objective to identify and progress new, potent and selective small molecule inhibitors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK